Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa

JAMA Dermatology

Volumn 152, Issue 4, 2016, Pages 429-434

  Egeberg, Alexander ^a   Gislason, Gunnar H ^a,b,c   Hansen, Peter R ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b The Danish Heart Foundation   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ALL CAUSE MORTALITY; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DANISH CITIZEN; DEATH; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT; SEX; SMOKING; SOCIAL STATUS; SUPPURATIVE HIDRADENITIS; CARDIOVASCULAR DISEASES; COMPLICATION; DENMARK; MIDDLE AGED; MYOCARDIAL INFARCTION; POISSON DISTRIBUTION; REGISTER; RISK FACTOR; STROKE;

ADULT; CARDIOVASCULAR DISEASES; COHORT STUDIES; DENMARK; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POISSON DISTRIBUTION; PSORIASIS; REGISTRIES; RISK FACTORS; STROKE;

EID: 84963748480     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.6264     Document Type: Article

References (42)

1. Jemec GB. Clinical practice: hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164.
2. Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;90(1062):216-221.
3. von derWerth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144(4):809-813.
4. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J; Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621-623.
5. Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2013;27 (4):473-478.
6. van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-aα, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-aα and IL-1β. Br J Dermatol. 2011;164(6):1292-1298.
7. Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J AmAcad Dermatol. 2011; 65(4):790-798.
8. Kelly G, Hughes R,Mc Garry T, et al. Dysregulated cytokine expression in lesional and non-lesional skin in hidradenitis suppurativa. Br J Dermatol. 2015;173(6):1431-1439.
9. Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-aα in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-aα agents? Acta Derm Venereol. 2009;89(6):601-603.
10. Riis PT, Søeby K, Saunte DM, Jemec GB. Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients. Arch Dermatol Res. 2015; 307(10):885-889.
11. Tzellos T, Zouboulis CC, Gulliver W, Cohen AD, Wolkenstein P, Jemec GB. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies [published online July 6, 2015]. Br J Dermatol.
12. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874.
13. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352 (16):1685-1695.
14. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147-157.
15. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk ofmyocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70(6):929-934.
16. Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Disease activity in inflammatory bowel disease is associated with increased risk ofmyocardial infarction, stroke and cardiovascular death-a Danish nationwide cohort study. PLoS One. 2013; 8(2):e56944.
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457.
18. Andersen TF, Madsen M, Jøgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3): 263-268.
19. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4): 445-448.
20. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-549.
21. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011;39(7)(suppl):103-105.
22. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health. 2011;39(7) (suppl):26-29.
23. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acutemyocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003;56(2):124-130.
24. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology. 2007;28 (3):150-154.
25. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011; 342:d124.
26. Egeberg A, Mallbris L, Gislason GH, Skov L, Hansen PR. Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study [published online September 9, 2015]. J Invest Dermatol.
27. Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1): 244-252.
28. Micheletti RG. Hidradenitis suppurativa: current views on epidemiology, pathogenesis, and pathophysiology. Semin Cutan Med Surg. 2014;33 (3)(suppl):S48-S50.
29. van der Zee HH, Laman JD, Boer J, Prens EP. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol. 2012;21(10):735-739.
30. Matusiak L, Batycka-Baran A, Bieniek A, Szepietowski JC. Decreased number of circulating endothelial progenitor cells in hidradenitis suppurativa patients. Dermatology. 2015;230(3): 228-233.
31. Miller IM, Johansen ME, Mogensen UB, Zarchi K, Ellervik C, Jemec GB. Coagulation status in hidradenitis suppurativa: a Danish population-and hospital-based cross-sectional study. Dermatology. 2015;231(2):119-126.
32. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015; 386(9997):983-994.
33. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644.
34. Campa M, Ryan C, Menter A. An overview of developing TNF-aα targeted therapy for the treatment of psoriasis. Expert Opin Investig Drugs. 2015;24(10):1343-1354.
35. Yang Y W, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol. 2011;165 (5):1037-1043.
36. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173-1179.
37. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2(1):9-16.
38. Richette P, Molto A, Viguier M, et al. Hidradenitis suppurativa associated with spondyloarthritis-results from a multicenter national prospective study. J Rheumatol. 2014;41 (3):490-494.
39. van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? results of a pilot study. Br J Dermatol. 2010;162(1): 195-197.
40. Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J AmAcad Dermatol. 2014;71 (6):1144-1150.
41. Charlson FJ, Moran AE, Freedman G, et al. The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment. BMC Med. 2013;11:250.
42. Coumbe AG, Pritzker MR, Duprez DA. Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am J Med. 2014;127(1):12-18.